Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Larimar Therapeutics (LRMR) Equity Ratio: 2013-2020

Historic Equity Ratio for Larimar Therapeutics (LRMR) over the last 7 years, with Sep 2020 value amounting to 0.90.

  • Larimar Therapeutics' Equity Ratio rose 39.72% to 0.90 in Q3 2020 from the same period last year, while for Sep 2020 it was 0.90, marking a year-over-year increase of 39.72%. This contributed to the annual value of -0.13 for FY2019, which is 117.42% down from last year.
  • Larimar Therapeutics' Equity Ratio amounted to 0.90 in Q3 2020, which was up 0.40% from 0.90 recorded in Q2 2020.
  • Over the past 5 years, Larimar Therapeutics' Equity Ratio peaked at 0.93 during Q1 2017, and registered a low of -0.13 during Q4 2019.
  • Moreover, its 3-year median value for Equity Ratio was 0.70 (2018), whereas its average is 0.67.
  • As far as peak fluctuations go, Larimar Therapeutics' Equity Ratio slumped by 117.42% in 2019, and later spiked by 39.72% in 2020.
  • Larimar Therapeutics' Equity Ratio (Quarterly) stood at 0.92 in 2016, then declined by 19.84% to 0.74 in 2017, then increased by 3.33% to 0.77 in 2018, then plummeted by 117.42% to -0.13 in 2019, then skyrocketed by 39.72% to 0.90 in 2020.
  • Its last three reported values are 0.90 in Q3 2020, 0.90 for Q2 2020, and 0.69 during Q1 2020.